Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

Barclays analyst Christopher Pasquale has initiated coverage on TransMedics Group (NASDAQ: TMDX) with an Overweight rating. The firm has set a price target of $120 for the company's stock.